ATE378329T1 - Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktion - Google Patents
Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktionInfo
- Publication number
- ATE378329T1 ATE378329T1 AT02753971T AT02753971T ATE378329T1 AT E378329 T1 ATE378329 T1 AT E378329T1 AT 02753971 T AT02753971 T AT 02753971T AT 02753971 T AT02753971 T AT 02753971T AT E378329 T1 ATE378329 T1 AT E378329T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- pyrrole
- methods
- type compounds
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30587001P | 2001-07-18 | 2001-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378329T1 true ATE378329T1 (de) | 2007-11-15 |
Family
ID=23182716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02753971T ATE378329T1 (de) | 2001-07-18 | 2002-07-18 | Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktion |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7144912B2 (de) |
| EP (1) | EP1427722B1 (de) |
| JP (1) | JP4303586B2 (de) |
| AT (1) | ATE378329T1 (de) |
| CA (1) | CA2453636A1 (de) |
| DE (1) | DE60223571T2 (de) |
| ES (1) | ES2304135T3 (de) |
| MX (1) | MXPA04000402A (de) |
| WO (1) | WO2003008410A2 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4980715B2 (ja) | 2003-05-30 | 2012-07-18 | ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド | がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法 |
| JP5224818B2 (ja) * | 2004-12-28 | 2013-07-03 | ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド | ジピロール化合物およびそれを含む医薬組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2673855A (en) | 1951-02-05 | 1954-03-30 | Commercial Solvents Corp | Prodigiosin gluconate |
| JPS55162758A (en) | 1979-04-02 | 1980-12-18 | Kissei Pharmaceut Co Ltd | Novel phenylacetamide derivative |
| JPS61280429A (ja) | 1985-06-06 | 1986-12-11 | Chugai Pharmaceut Co Ltd | 免疫抑制剤 |
| JPH02250828A (ja) | 1989-03-23 | 1990-10-08 | Nippon Kayaku Co Ltd | 新規免疫抑制剤 |
| GB9326284D0 (en) | 1993-12-23 | 1994-02-23 | Erba Carlo Spa | Pyrrolydenemethyl-derivatives and process for their preparation |
| JPH0930967A (ja) | 1995-07-17 | 1997-02-04 | Chugai Pharmaceut Co Ltd | 抗潰瘍剤 |
| GB9603212D0 (en) | 1996-02-15 | 1996-04-17 | Pharmacia Spa | Process for the preparation of 2,2'-bipyrrolyl-pyrromethane derivatives |
| GB9619706D0 (en) | 1996-09-20 | 1996-11-06 | Pharmacia Spa | Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole comp und |
| JP3949198B2 (ja) | 1996-10-23 | 2007-07-25 | 赤穂化成株式会社 | Ｖ−ＡＴＰａｓｅ 脱共役 Ｈ＋ ポンプ阻害剤 |
| JP3949196B2 (ja) | 1996-10-23 | 2007-07-25 | 赤穂化成株式会社 | 免疫抑制剤 |
| GB9705035D0 (en) | 1997-03-11 | 1997-04-30 | Pharmacia & Upjohn Spa | Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation |
| KR100252197B1 (ko) | 1997-09-20 | 2000-04-15 | 박호군 | 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신 |
| JPH11209283A (ja) | 1997-10-01 | 1999-08-03 | Ako Kasei Co Ltd | 抗癌剤 |
| GB9726130D0 (en) | 1997-12-10 | 1998-02-11 | Pharmacia & Upjohn Spa | 2,2'-BI-1H-pyrrole derivatives useful in the treatment of leukemia brought on by HTLV-I |
| GB9802745D0 (en) | 1998-02-09 | 1998-04-08 | Pharmacia & Upjohn Spa | Benzyloxy prodigiosine compounds |
| US6359096B1 (en) * | 1999-10-25 | 2002-03-19 | Dow Corning Corporation | Silicone resin compositions having good solution solubility and stability |
| US6407244B1 (en) * | 2000-01-26 | 2002-06-18 | Gemin X Biotechnologies Inc. | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases |
| KR20010081515A (ko) | 2000-02-15 | 2001-08-29 | 복성해 | 프로디지오신의 당뇨병 예방 및 치료용 조성물 |
| US20030119894A1 (en) * | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
-
2002
- 2002-07-18 AT AT02753971T patent/ATE378329T1/de not_active IP Right Cessation
- 2002-07-18 WO PCT/CA2002/001104 patent/WO2003008410A2/en not_active Ceased
- 2002-07-18 DE DE60223571T patent/DE60223571T2/de not_active Expired - Lifetime
- 2002-07-18 JP JP2003513969A patent/JP4303586B2/ja not_active Expired - Fee Related
- 2002-07-18 CA CA002453636A patent/CA2453636A1/en not_active Abandoned
- 2002-07-18 US US10/484,652 patent/US7144912B2/en not_active Expired - Fee Related
- 2002-07-18 MX MXPA04000402A patent/MXPA04000402A/es unknown
- 2002-07-18 EP EP02753971A patent/EP1427722B1/de not_active Expired - Lifetime
- 2002-07-18 ES ES02753971T patent/ES2304135T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7144912B2 (en) | 2006-12-05 |
| JP2004536861A (ja) | 2004-12-09 |
| MXPA04000402A (es) | 2004-03-18 |
| WO2003008410A2 (en) | 2003-01-30 |
| US20050049292A1 (en) | 2005-03-03 |
| EP1427722B1 (de) | 2007-11-14 |
| EP1427722A2 (de) | 2004-06-16 |
| DE60223571T2 (de) | 2008-07-24 |
| WO2003008410A3 (en) | 2003-07-17 |
| CA2453636A1 (en) | 2003-01-30 |
| WO2003008410A8 (en) | 2004-04-01 |
| DE60223571D1 (de) | 2007-12-27 |
| JP4303586B2 (ja) | 2009-07-29 |
| ES2304135T3 (es) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE546456T1 (de) | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs | |
| ATE530561T1 (de) | 3-ether- und 3-thioether-substituierte ciclosporinderivate zur behandlung und prävention einer hepatitis-c-infektion | |
| IS7533A (is) | Lifrarbólgu C-veirutálmar | |
| ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
| EA202191223A1 (ru) | НОВЫЕ 6,7-ДИГИДРО-4Н-ПИРАЗОЛО[1,5-а]ПИРАЗИН-ИНДОЛ-2-КАРБОКСАМИДЫ, АКТИВНЫЕ ПРОТИВ ВИРУСА ГЕПАТИТА B (HBV) | |
| ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| MXPA03000627A (es) | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. | |
| ES2051641B1 (es) | Procedimientos para la preparacion de compuestos derivados de tiourea. | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| EA200500723A1 (ru) | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита c, и связанных с ним заболеваний | |
| EA202192512A1 (ru) | Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv | |
| DE60211539D1 (de) | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion | |
| DE602006020152D1 (de) | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion | |
| MXPA02007271A (es) | Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales. | |
| DE60231475D1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
| ATE432936T1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| WO2005117908A3 (en) | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases | |
| ATE378329T1 (de) | Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktion | |
| WO2005084315A3 (en) | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease | |
| DK0470989T3 (da) | Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer | |
| EA202192965A1 (ru) | Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
| EA202192968A1 (ru) | Новые фенил- и пиридилмочевины, активные против вируса гепатита b (вгв) | |
| EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |